Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases

Digestive and Liver Disease

Volumn 45, Issue 12, 2013, Pages 1003-1010

  Tavano, Francesca ^a   Palmieri, Orazio ^a   di Mola, Fabio Francesco ^a,c   Latiano, Anna ^a   Burbaci, Francesca Paola ^a   Valvano, Maria Rosa ^a   Corritore, Giuseppe ^a   Augello, Bartolomeo ^a   Merla, Giuseppe ^a   Annese, Vito ^a,b   Andriulli, Angelo ^a   di Sebastiano, Pierluigi ^a,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c SS Annunziata Hospital   (Italy)

Author keywords

Inflammatory bowel disease; Neurokinin 1 receptor; Neutral endopeptidase; Substance P

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; NEUROKININ 1 RECEPTOR; SUBSTANCE P;

ADULT; ARTICLE; COLON MUCOSA; COLON RESECTION; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMMUNOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ULCERATIVE COLITIS;

INFLAMMATORY BOWEL DISEASE; NEUROKININ-1 RECEPTOR; NEUTRAL ENDOPEPTIDASE; SUBSTANCE P;

ADULT; ANUS DISEASES; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; GENE FREQUENCY; GENOTYPE; HUMANS; INTESTINAL MUCOSA; NEPRILYSIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NEUROKININ-1; RNA, MESSENGER; SMOKING; SUBSTANCE P; TACHYKININS; YOUNG ADULT;

EID: 84887152735     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.05.010     Document Type: Article

References (49)

1. Podolsky D. Inflammatory bowel disease. The New England Journal of Medicine 2002, 347:417-429.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
3. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. American Journal of Physiology 1997, 273:G769-G775.
4. Neunlist M., Van Landeghem L., Bourreille A., et al. Neuro-glial crosstalk in inflammatory bowel disease. Journal of Internal Medicine 2008, 263:577-583.
5. Gross K.J., Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflammatory Bowel Disease 2007, 13:918-932.
6. Margolis K.G., Gershon M.D. Neuropeptides and inflammatory bowel disease. Current Opinion in Gastroenterology 2009, 25:503-511.
7. McGillis J.P., Mitsuhashi M., Payan D.G. Immunomodulation by tachykinin neuropeptides. Annals of the New York Academy of Sciences 1990, 594:85-94.
8. Di Sebastiano P., Fink T., di Mola F.F., et al. Neuroimmune appendicitis. The Lancet 1999, 354:461-466.
9. Kraneveld A.D., Nijkamp F.P. Tachykinins and neuro-immune interactions in asthma. International Immunopharmacology 2001, 1:1629-1650.
10. Di Sebastiano P., di Mola F.F., Bockman D.E., et al. Chronic pancreatitis: the perspective of pain generation by neuroimmune interaction. Gut 2003, 52:907-911.
11. Liu L., Markus I., Saghire H.E., et al. Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1?. Neurogastroenterology & Motility 2011, 5:475-483.
12. di Mola F.F., Friess H., Zhu Z.W., et al. Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease. Gut 2000, 46:670-679.
13. Geboes K., Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterology & Motility 1998, 10:189-202.
14. Villanacci V., Bassotti G., Nascimbeni R., et al. Enteric nervous system abnormalities in inflammatory bowel disease. Neurogastroenterology & Motility 2008, 20:1009-1016.
15. Sanovic S., Lamb D.P., Blennerhassett M.G. Damage to the enteric nervous system in experimental colitis. The American Journal of Pathology 1999, 155:1051-1057.
16. te Velde A.A., Verstege M.I., Hommes D.W. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflammatory Bowel Disease 2006, 12:995-999.
17. Tavano F., di Mola F.F., Latiano A., et al. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on substance P serum levels. Journal of Crohn's and Colitis 2012, 6:563-570.
18. Renzi D., Mantellini P., Calabro A., et al. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are decreased in patients with moderate and severe ulcerative colitis. Italian Journal of Gastroenterology and Hepatology 1998, 30:62-67.
19. Watanabe T., Kubota Y., Muto T., Substance P containing nerve fibers in ulcerative colitis. International Journal of Colorectal Disease 1998, 13:61-67.
20. Azzolina A., Bongiovanni A., Lampiasi N., Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochimica et Biophysica Acta 2003, 1643:75-83.
21. Fiebich B.L., Schleicher S., Butcher R.D., et al. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. Journal of Immunology 2000, 165:5606-5611.
22. Lieb K., Fiebich B.L., Berger M., et al. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. Journal of Immunology 1997, 159:4952-4958.
23. Di Sebastiano P., Grossi L., di Mola F.F., et al. SR 140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Digestive Diseases and Sciences 1999, 44:439-444.
24. Pereira N.L., Aksoy P., Moon I., et al. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. Journal of Molecular and Cellular Cardiology 2010, 49:864-874.
25. Hwang L., Leichter R., Okamoto A., et al. Downregulation of neutral endopeptidase (EC 3.4.24.11) in the inflamed rat intestine. American Journal of Physiology 1993, 264:G735-G743.
26. Bernstein C.N., Robert M.E., et al. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. American Journal of Gastroenterology 1993, 88:908-913.
27. Mazumdar S., Das K.M. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. American Journal of Gastroenterology 1992, 87:176-181.
28. Keränen U., Kiviluoto T., Järvinen H., et al. Changes in substance P-immunoreactive innervation of human colon associated with ulcerative colitis. Digestive Diseases and Sciences 1995, 40:2250-2258.
29. Kimura M., Masuda T., Hiwatashi N., et al. Changes in neuropeptidecontaining nerves in human colonic mucosa with inflammatory bowel disease. Pathology International 1994, 44:624-634.
30. Koch T.R., Carney J.A., Go V.L. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Digestive Diseases and Sciences 1987, 32:369-376.
31. Michalski C.W., Autschbach F., Selvaggi F., et al. Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease. American Journal of Surgery 2007, 193:476-481.
32. Cunningham S., Patterson C.C., McDonnell G., et al. Haplotype analysis of the preprotachykinin-1 (TAC1) gene in multiple sclerosis. Genes Immunity 2005, 6:265-270.
33. Cunningham S., O'Doherty C., Patterson C., et al. The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP (ADCYAP1), and susceptibility to multiple sclerosis. Journal of Neuroimmunology 2007, 183:208-213.
34. Marui T., Funatogawa I., Koishi S., et al. Tachykinin 1 (TAC1) gene SNPs and haplotypes with autism: a case-control study. Brain Development 2007, 29:510-513.
35. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1989, 24(Suppl. 170):2-6.
36. Shivananda S., Hordijk M.L., Ten Kate F.J., et al. Differential diagnosis of inflammatory bowel disease. A comparison of various diagnostic classifications. Scandinavian Journal of Gastroenterology 1991, 26:167-173.
37. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology 2005, 19:5-36.
38. Satsangi J., Silverberg M.S., Vermeire S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
39. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 2nd ed.
40. Cucchiara S., Latiano A., Palmieri O., et al. Polymorphisms of tumour necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 2007, 44:171-179.
41. Senchaudhuri P., Mehta C.R., Patel N.R. Estimating exact p values by the method of control variates, or Monte Carlo rescue. Journal of the American Statistical Association 1995, 90:640-648.
42. Mehta C.R., Patel N.R., Senchaudhuri P. Importance sampling for estimating exact probabilities in permutational inference. Journal of the American Statistical Association. 1988, 83:999-1005.
43. Westfall P.H., Young S.S. Resampling-based multiple testing: examples and methods for p value adjustment 1993, John Wiley and Sons, New York.
44. Birrenbach T., Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflammatory Bowel Disease 2004, 10:848-859.
45. Eliakim R., Fan Q.X., Babyatsky M.W. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. European Journal of Gastroenterology and Hepatology 2002, 14:607-614.
46. Eliakim R., Karmeli F., Cohen P., et al. Dual effect of chronic nicotine administration: augmentation of jejunitis and amelioration of colitis induced by iodoacetamide in rats. International Journal of Colorectal Disease 2001, 16:14-21.
47. Van Dijk J.P., Madretsma G.S., Keuskamp Z.J., et al. Nicotine inhibits cytokine synthesis by mouse colonic mucosa. European Journal of Pharmacology 1995, 278:R11-R12.
48. Anderson C.A., Boucher G., Lees C.W., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics 2011, 43:246-252.
49. Franke A., McGovern D.P., Barrett J.C., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics 2010, 42:1118-1125.